<div>Health-care companies ticked up as traders rotated back into higher risk sectors.

 Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a new pill called orforglipron that has helped clinical-trial participants lose weight. 

 Danish rival Novo Nordisk, meanwhile, filed for FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity. CagriSema combines the main ingredient in Wegovy with cagrilintide, an experimental drug that mimics the amylin hormone, the body's appetite regulator. 

 Cannabis producers such as Tilray and Canopy Growth fell after President Donald Trump signed an executive order to reschedule marijuana as a lower-class drug, stopping short of permitting recreational sales. 
 Write to Rob Curran at rob.curran@dowjones.com 

 (END) Dow Jones Newswires12-18-25 1741ET</div>

諾和諾德公司

禮來

醫療股小幅上漲，因為交易者轉向風險較高的行業。禮來和諾和諾德公司申請了 FDA 對新型肥胖治療藥物的批准。由於特朗普重新安排了大麻的分類，影響了休閒銷售， cannabis 股票下跌

醫療保健板塊上漲，但漲幅有限，因交易員尋求風險——醫療保健綜述